ArticleScientific reports2015
Erythropoietin alleviates hepatic insulin resistance via PPARγ-dependent AKT activation.
Article in Scientific reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 40 citations in OpenAlex.
- Hepatocyte hedgehog signaling controls ferroptosis to alleviate aging-related organ dysfunction.JCI insight · 2026Article
- Erythropoietin modulates hepatic inflammation, glucose homeostasis, and soluble epoxide hydrolase and epoxides in high-fat diet-induced obese mice.FEBS open bio · 2026Article
- A direct effect of the hematocrit on blood glucose: Evidence from hypoxia- and erythropoietin-treated mice.Science advances · 2025Article
- Review
- Study on the effect and mechanism of Ershiyiwei Lvronghao concentrated Pills in the treatment of nonalcoholic fatty liver disease.Frontiers in pharmacology · 2025Article
- Non-hematopoietic roles of erythropoietin in inflammation and metabolic disorders.Frontiers in pharmacology · 2025Review
- Article
- Erythropoietin regulates osteoclast formation via up-regulating PPARγ expression.Molecular medicine (Cambridge, Mass.) · 2024Article
- N-Frontiers in pharmacology · 2024Article
- Erythropoietin Suppresses the Hepatic Fibrosis Caused by Thioacetamide: Role of the PI3K/Akt and TLR4 Signaling Pathways.Oxidative medicine and cellular longevity · 2023Article
- The Common Single Cause of Chronic Multi-Hormonal Resistance in Oxidative Stress.Antioxidants (Basel, Switzerland) · 2022Review
- Berberrubine, a Main Metabolite of Berberine, Alleviates Non-Alcoholic Fatty Liver DiseaseFrontiers in pharmacology · 2022Article
- Oleic Acid and Eicosapentaenoic Acid Reverse Palmitic Acid-induced Insulin Resistance in Human HepG2 Cells via the Reactive Oxygen Species/JUN Pathway.Genomics, proteomics & bioinformatics · 2021Article
- Regulation of muscle and metabolic physiology by hypothalamic erythropoietin independently of its peripheral action.Molecular metabolism · 2020Article
- Characterization and Treatment of Inflammation and Insulin Resistance in Obese Adipose Tissue.Diabetes, metabolic syndrome and obesity : targets and therapy · 2020Review
- Erythropoietin suppresses hepatic steatosis and obesity by inhibiting endoplasmic reticulum stress and upregulating fibroblast growth factor 21.International journal of molecular medicine · 2019Article
- Potential use of transgenic domestic pigs expressing recombinant human erythropoietin in diabetes translation research.Animal cells and systems · 2019Article
- GSK3β: a plausible mechanism of cognitive and hippocampal changes induced by erythropoietin treatment in mood disorders?Translational psychiatry · 2018Review
- PPARPPAR research · 2018Article
- A central role for hypoxia-inducible factor (HIF)-2α in hepatic glucose homeostasis.Nutrition and healthy aging · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Erythropoietin (EPO) has beneficial effects on glucose metabolism and insulin resistance. However, the mechanism underlying these effects has not yet been elucidated. This study aimed to investigate how EPO affects hepatic glucose metabolism. Here, we report that EPO administration promoted phosphatidylinositol 3-kinase (PI3K)/AKT pathway activation in palmitic acid (PA)-treated HepG2 cells and in the liver of high-fat diet (HFD)-fed mice, whereas adenovirus-mediated silencing of the erythropoietin receptor (EPOR) blocked EPO-induced AKT signalling in HepG2 cells. Importantly, a peroxisome proliferator-activated receptor γ (PPARγ) antagonist and PPARγ small interfering RNA (siRNA) abrogated the EPO-induced increase in p-AKT in HepG2 cells. Lentiviral vector-mediated hepatic PPARγ silencing in HFD-fed C57BL/6 mice impaired EPO-mediated increases in glucose tolerance, insulin sensitivity and hepatic AKT activation. Furthermore, EPO activated the AMP-activated protein kinase (AMPK)/sirtuin 1 (SIRT1) signalling pathway, and AMPKα and SIRT1 knockdown each attenuated the EPO-induced PPARγ expression and deacetylation and PPARγ-dependent AKT activation in HepG2 cells. In summary, these findings suggest that PPARγ is involved in EPO/EPOR-induced AKT activation, and targeting the PPARγ/AKT pathway via EPO may have therapeutic implications for hepatic insulin resistance and type 2 diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.